Financial Performance and Dividends - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 204,860,291.75 (including tax), with a total cash dividend payout of RMB 689,379,549.53 for 2023, accounting for 34.92% of the net profit attributable to shareholders[8] - Revenue for 2023 reached RMB 11.41 billion, a 23.52% increase compared to 2022[23] - Net profit attributable to shareholders in 2023 was RMB 1.97 billion, up 19.21% year-over-year[23] - Operating cash flow in 2023 was RMB 132.51 million, a significant decrease of 80.59% compared to 2022[23] - Total assets at the end of 2023 stood at RMB 25.34 billion, a 4.68% increase from the previous year[23] - The company's equity attributable to shareholders increased by 7.91% to RMB 18.87 billion at the end of 2023[23] - Basic earnings per share increased by 9.59% to 2.40 yuan per share in 2023 compared to 2022[24] - Net profit attributable to the parent company increased by 19.21% to 19.74 billion yuan in 2023[25] - R&D investment accounted for 16.81% of operating income, an increase of 0.94 percentage points from 2022[25] - Total operating revenue reached 114.11 billion yuan in 2023, a year-on-year increase of 23.52%[25] - Net profit attributable to the parent company after deducting non-recurring gains and losses increased by 25.38% to 16.65 billion yuan in 2023[25] - Total assets at the end of 2023 were 253.36 billion yuan, a year-on-year increase of 4.68%[25] - Equity attributable to the parent company at the end of 2023 was 188.66 billion yuan, a year-on-year increase of 7.91%[25] - Operating cash flow in the fourth quarter of 2023 was 974.60 million yuan, a significant improvement compared to previous quarters[29] - Government subsidies received in 2023 amounted to 235.42 million yuan, a decrease from 335.56 million yuan in 2022[30] - Revenue increased by 23.52% to RMB 11,410,765,602.39 compared to the previous year[115] - Operating costs rose by 23.24% to RMB 5,878,580,949.27[115] - R&D expenses grew by 32.33% to RMB 1,728,541,428.81 due to increased investment in research and development[115] - Sales expenses increased by 33.28% to RMB 1,769,512,581.90, driven by higher sales personnel costs and travel expenses[115] - Net cash flow from operating activities decreased by 80.59% to RMB 132,511,079.76[115] - The gross profit margin for the medical device industry increased by 0.12 percentage points to 48.99%[117] - Revenue from medical imaging diagnostic and radiotherapy equipment sales grew by 21.10% to RMB 9,927,400,522.47[117] - Revenue from maintenance services increased by 42.78% to RMB 1,069,374,958.28, with a gross profit margin increase of 5.93 percentage points[117] - Software revenue surged by 124.85% to RMB 174,468,152.21, with a gross profit margin increase of 12.82 percentage points[117] - Domestic revenue accounted for RMB 9,512,035,184.75, a 19.70% increase from the previous year[117] - Total revenue from medical imaging and radiotherapy equipment sales reached 9.927 billion yuan, a year-on-year increase of 21.10%[119] - MR equipment sales revenue increased by 58.50% year-on-year to 3.279 billion yuan[119] - XR equipment sales revenue grew by 32.83% year-on-year to 760.18 million yuan[119] - Maintenance service revenue increased by 42.78% year-on-year to 1.069 billion yuan[119] - Software revenue surged by 124.85% year-on-year to 174.47 million yuan[119] - Domestic revenue grew by 19.70% to 9.512 billion yuan, while overseas revenue increased by 53.97% to 1.659 billion yuan[119] - Direct material costs accounted for 89.08% of total costs, increasing by 25.11% year-on-year[122] - Direct labor costs rose by 40.74% year-on-year, with equipment-related labor costs increasing by 54.79%[123] - Top five customers accounted for 9.91% of total sales, with no sales to related parties[125] - The top 5 suppliers accounted for 7.27% of the total annual procurement amount, with the largest supplier contributing 31,651.84 thousand RMB, representing 2.00% of the total procurement[129] - Sales expenses increased by 33.28% to 1,769,512,581.90 RMB, driven by higher sales personnel costs and travel/conference expenses[130] - R&D expenses rose by 32.33% to 1,728,541,428.81 RMB due to increased investment in R&D materials and personnel costs[130] - Net cash flow from operating activities decreased by 80.59% to 132,511,079.76 RMB, primarily due to increased raw material procurement, labor costs, and tax payments[131] - Net cash flow from financing activities dropped by 106.17% to -662,170,739.78 RMB, mainly due to the completion of the IPO in the previous year and the implementation of share repurchases and dividend distributions[132] - Accounts receivable increased by 60.34% to 3,227,657,250.54 RMB, accounting for 12.74% of total assets, driven by higher sales[133] - Overseas assets amounted to 1,390,810,078.55 RMB, representing 5.49% of total assets[135] - The company invested 52,591,941.34 RMB in equity investments during the reporting period, a 26,195.97% increase compared to the previous year[138] - The next-generation R&D product project has a total estimated investment of 6.168 billion RMB, with a progress rate of 21.27%[139] Technological Innovation and R&D - The company aims to accelerate the application of new productive forces by integrating AI and information technology with innovative imaging, radiotherapy, and interventional equipment[4] - The company is committed to advancing technological innovation, including AI, 5G, and IoT, to enhance the integration of high-end medical equipment and develop globally competitive super equipment[2] - The company is exploring the application of circular economy models in the medical industry to reduce resource consumption and environmental pollution throughout the product lifecycle[2] - The company emphasizes the importance of deep collaboration between industry, academia, and medical institutions to drive innovation and solve broader medical challenges[2] - The company highlights the growth potential of China's healthcare industry, which is transitioning to a high-quality development phase, creating opportunities for digital and AI-driven medical solutions[3] - The company successfully launched multiple innovative products in 2023, further consolidating its leading market position[33] - R&D investment accounted for 16.81% of total revenue, an increase of 0.94 percentage points year-over-year[34] - Over 120 products have been launched, with 20+ new hardware and software products receiving NMPA registration in China[34] - Cumulative patent applications exceeded 9,900, with over 80% being invention patents, and over 5,100 intellectual property authorizations, including more than 3,000 invention patents[35] - The company's total R&D investment in 2023 reached 1,918,617,388.39 yuan, a 30.84% increase compared to the previous year[87] - R&D investment as a percentage of revenue increased to 16.81%, up 0.94 percentage points from the previous year[87] - The company has accumulated 9,944 intellectual property applications, with 5,160 granted, including 6,953 invention patent applications and 3,029 granted[84][85] - In 2023, the company added 1,226 new intellectual property applications, with 967 granted, including 956 invention patent applications and 729 granted[84][85] - The company has 45 ongoing R&D projects with a total planned investment of 4,388 million yuan, and a cumulative investment of 3,016.16 million yuan by the end of 2023[89][90] - The MR R&D project series has a total planned investment of 1,040 million yuan, with a cumulative investment of 959.9 million yuan by the end of 2023[89] - The CT R&D project series has a total planned investment of 2,500 million yuan, with a cumulative investment of 2,053.03 million yuan by the end of 2023[89] - The RT R&D project series has a total planned investment of 3,650 million yuan, with a cumulative investment of 2,628.62 million yuan by the end of 2023[89] - The software R&D project series has a total planned investment of 2,450 million yuan, with a cumulative investment of 1,395.9 million yuan by the end of 2023[89] - The XR R&D project series has a total planned investment of 1,500 million yuan, with a cumulative investment of 1,130.58 million yuan by the end of 2023[89] - The number of R&D personnel decreased from 3,088 to 2,956, accounting for 39.73% of the total workforce, down from 42.29% in the previous period[91] - Total R&D personnel compensation increased to RMB 131,448.48 thousand, with an average salary of RMB 44.47 thousand, up from RMB 34.25 thousand[91] - The company has a comprehensive product portfolio covering MR, CT, XR, PET/CT, PET/MR, and RT, with several industry-first products such as the uEXPLORER Total-body PET/CT and uMR Jupiter 5T[93][94] - The company has established a vertical R&D system and a platform-based R&D model, enabling self-developed core components and efficient product iteration[95] - As of the reporting period, the company had 2,956 R&D personnel, representing 39.73% of the total workforce[96] - The company has filed over 9,900 intellectual property applications, with over 80% being invention patents, and has been granted over 5,100 intellectual property rights, including over 3,000 invention patents[97] - The company's R&D model follows medical device regulatory requirements and ISO quality system standards, with a structured product development process[62] - The company maintains a safety stock for mass-produced materials and collaborates with suppliers for non-mass-produced and long-lead-time materials to ensure timely supply[63] - The company uses information technology to build an intelligent production system, improving efficiency and reducing costs[64] - The company has developed the industry's first 75cm large-aperture 3.0T and 5.0T whole-body MRI products, as well as the first domestically produced 3.0T MR and 9.4T animal MR products[70] - The company's self-developed spatiotemporal detector supports a minimum slice thickness of 0.5mm and is used in its CT series products[71] - The company has developed an AI-based full-model iterative reconstruction algorithm for CT products, which maximizes dose reduction while meeting clinical diagnostic requirements[71] - The company's high-resolution detector technology in molecular imaging can effectively improve image quality, scanning speed, and reduce scanning dose[71] - The company's 6MV accelerator tube achieves a maximum dose rate of 600MU/min@1m in flattened mode and 1400MU/min@1m in unflattened mode, leading the industry[71] - The company's product line covers high-end medical imaging diagnostic products and radiotherapy products, achieving an integrated diagnosis and treatment layout[72] - The company is one of the few in the industry capable of designing and manufacturing long-axis PET products[71] - The company's dynamic multi-leaf collimator technology enables efficient and precise volumetric intensity-modulated radiation therapy, reducing radiation dose to normal tissues[71] - The company is a major player in the Chinese medical imaging and radiotherapy equipment market, ranking second in CT market share, third in MR market share, and first in PET/CT and PET/MR market share[73] - In the CT market, the company ranks first in market share for 40-row and below CTs, first for 41-63 row CTs, and third for 64-row and above CTs[73] - In the MR market, the company ranks second in market share for 1.5T and below superconducting MRs, third for 3.0T MRs, and first for 3.0T and above ultra-high-field MRs[73] - The company holds the top market share in diagnostic XR products (including fixed DR, mobile DR, and breast DR) in China, with first place in fixed DR and breast DR, and second place in mobile DR[73] - In the radiotherapy equipment market, the company ranks third in market share for RT products[73] - The company is one of the few global companies with core technology and complete machine production capabilities for 5.0T and above MR systems[75] - The company has mastered key technologies such as sub-millimeter unit resolution, depth effect recognition and correction, and online scatter effect recovery for animal PET/CT systems[75] - The company's RT products feature image-guided radiotherapy, enabling precise targeting of tumors and adaptive treatment planning based on tumor changes[75] - The company is developing high-sensitivity acquisition, molecular imaging, and fast imaging technologies for preclinical MRI systems[75] - The company is advancing digital PET/CT technology using Silicon Photomultiplier (SiPM) to improve spatial resolution, sensitivity, and count rate characteristics[75] - The company has mastered the core technology of 5.0T and above high-field human superconducting magnets, achieving a 75cm large patient aperture 3.0T superconducting magnet for the first time[76] - The gradient strength of the high-performance gradient coil design and production technology ranges from 33mT/m to 120mT/m, with a gradient switching speed of 125T/m/s to 220T/m/s, leading the industry[76] - The full digital megawatt-level gradient power amplifier (GPA) technology covers a power range from 0.7 megawatts to 3.5 megawatts, achieving industry-leading levels[76] - The full digital radio frequency power amplifier (RFPA) technology uses all-solid-state power amplification and high-density, high-integration structural optimization to reduce size and cost[76] - The high-field multi-channel RF transmission technology enables independent control of multiple channels, improving RF transmission magnetic field uniformity[76] - The RF reception coil design and production technology covers all body parts with high-channel dedicated reception coils, leading the industry[76] - The distributed spectrometer and fiber optic digital transmission technology achieves industry-leading levels in high reception channel count and signal stability[76] - The magnetic resonance rapid imaging technology platform achieves 0.5 seconds per phase rapid dynamic high-definition imaging, a first in the industry[76] - The magnetic resonance automation scanning technology enables intelligent scanning of various body parts, including the head, heart, spine, and abdomen[76] - The magnetic resonance advanced application and post-processing technology includes industry-first advanced application technologies such as complex domain diffusion reconstruction and multi-echo advanced magnetic susceptibility weighted imaging[76] - The company's full-view cone-beam CT reconstruction technology expands the reconstruction field of view to 431mm, achieving full abdominal coverage[78] - The digital light guide PET detector design achieves industry-leading sensitivity and spatial resolution using SiPM and LYSO crystals[79] - The company's high-precision PET detector calibration technology improves signal processing accuracy and image quality, maintaining system stability[79] - The parallel image reconstruction method based on GPU acceleration significantly enhances computational speed and quantitative accuracy[79] - The AI-based reconstruction algorithm reduces image noise, improves image quality, and shortens scan time[79] - The AI-based attenuation correction technology includes body skeletal information, significantly improving image quality and quantitative accuracy[79] - The motion artifact reduction technology effectively minimizes PET image artifacts caused by respiratory and head movements[79] - The tumor analysis technology supports PERCIST and RECIST standards, enabling rapid and accurate diagnosis of tumor diseases[79] - The parameter imaging and analysis technology provides quantitative drug metabolism analysis based on multiple models[79] - The company's multi-scale image enhancement and equalization technology in static DR imaging highlights lesion locations[78] - High dose rate dual-beam accelerator technology achieves a maximum output of over 1400 MU/min in FFF mode, significantly improving treatment efficiency[80] - The precision dose control system achieves a minimum control dose follow-up accuracy of less than 0.1 MU and long-term stability of less than 1%[80] - The dynamic multi-leaf collimator system achieves a repeat positioning accuracy of less than 0.5mm and supports real-time dynamic control[80] - The integrated CT imaging technology enables precise registration before treatment and real-time monitoring of dose distribution during treatment[80] - The high-precision treatment bed achieves the longest motion range, highest stiffness, and smallest error in the industry[80] - The Monte Carlo dose calculation algorithm achieves routine plan calculations in less than 1 minute[80] - The cross-modal software workflow technology improves clinical efficiency and reduces learning costs for end-users[81] - The 3D medical imaging visualization engine technology achieves ultra-high resolution and real-time rendering with zero waiting time[81] - The complex electromagnetic environment hardware circuit design technology supports high-speed data acquisition at 39*4Gps in a 0.25s rotation[81] - The high-precision cooling temperature control technology achieves precise temperature control for core components and system-level temperature management[82] Global Expansion and Subsidiaries - United Imaging Healthcare has a wide range of subsidiaries globally, including in the UK, Hong Kong, UAE, Korea, Poland, Japan, Malaysia, South Africa, Morocco, Kazakhstan, Singapore, Colombia, Indonesia, and the US[13] - The company has significant holdings in subsidiaries such as UIH America, Inc., United Imaging Healthcare Japan, and United Imaging Healthcare (Australia & New Zealand) Pty Ltd[13] - United Imaging Healthcare has strategic partnerships with entities like Shenzhen High-Performance Medical Devices National Research Institute Co., Ltd. and Wuhan Zhongke Medical Technology Industrial Technology Research Institute Co., Ltd.[13] - The company's subsidiaries are involved in

关于上海联影医疗科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 委托单位：上海联影医疗科技股份有限公司 审计单位：普华永道中天会计师事务所（特殊普通合伙） 1、 专项审计报告 2、 附表 普华永道 关于上海联影医疗科技股份有限公司 控股股东及其他关联方占用资金情况专项报告 普华永道中天特审字(2024)第2096号 (第一页,共二页) 根据中国证券监督管理委员会《上市公司监管指引第 8 号 -- 上市公司资金 往来、对外担保的监管要求》和《公开发行证券的公司信息披露内容与格式准则 第 2 号 -- 年度报告的内容与格式(2021年修订)》及上海证券交易所《上海 证券交易所科创板上市公司自律监管指南(2023年12月第二次修订) -- 第 7 号 年度报告相关事项》的要求,联影医疗编制了上述情况表。设计、执行和维 护与编制和列报情况表有关的内部控制、采用适当的编制基础如实编制和对外披 露情况表并确保其真实性、合法性及完整性是联影医疗管理层的责任。 普华永道中天会计师事务所(特殊普通合伙) 中国上海市黄浦区湖滨路202号领展企业广场2座普华永道中心11楼 邮编200021 ...

中信证券股份有限公司、中国国际金融股份有限公司 关于上海联影医疗科技股份有限公司 关于开展以套期保值为目的的外汇衍生品交易的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐机构"）、中国国际金 融股份有限公司（以下简称"中金公司"、"保荐机构"）为上海联影医疗科技股份 有限公司（以下简称"公司"、"联影医疗"）首次公开发行股票并上市的保荐机构。 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市规 则（2023 年修订）》等相关规定履行持续督导职责，对联影医疗开展以套期保值 为目的的外汇衍生品交易的事项进行了核查，核查情况及核查意见如下： 公司用于开展外汇衍生品交易业务的资金来源为公司自有资金，不涉及使用 募集资金开展外汇衍生品交易业务的情况。 （四）交易方式 1、交易品种：拟开展的外汇衍生品交易品种包括但不限于外汇远期结售汇 业务、外汇掉期业务、外汇期权业务等。 一、交易情况 （一）交易目的 公司出口产品和进口原材料主要以外币结算，基于公司全球化业务布局的稳 步发展及外汇市场波动性，为提高公司应对外汇波动风险的能力，防范和降低汇 率波动风险，增强公司财务稳健性，降低汇率波动对公 ...

根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等要求，上海联影医疗科技股份有限公司（以下 简称"公司"）董事会，就公司截至本意见出具日在任的以及 2023 年度在任独立 董事 JIA HONG GAO、王少飞、盛雷鸣的独立性情况进行评估并出具如下专项意 见： 上海联影医疗科技股份有限公司董事会 关于独立董事独立性情况的专项意见 上海联影医疗科技股份有限公司董事会 2024 年 4 月 25 日 经核查独立董事 JIA HONG GAO、王少飞、盛雷鸣及其直系亲属和主要社会 关系人员的任职经历以及独立董事签署的相关自查文件，独立董事 JIA HONG GAO、 王少飞、盛雷鸣不存在《上市公司独立董事管理办法》第六条不得担任独立董事 的情形，在担任公司独立董事期间，独立董事已严格遵守中国证监会和上海证券 交易所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责，作出独立判 断，不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个人的 影响。公司独立董事 JIA HONG GAO、王少飞、盛雷鸣符合《上市公司独立董事管 理办法》《上海证券交易所科创板 ...

上海联影医疗科技股份有限公司 第二届董事会第六次会议决议公告 证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）第二 届董事会第六次会议于 2024 年 4 月 25 日在公司会议室召开，会议同时采用了现 场与通讯相结合的表决方式，本次会议通知已于 2024 年 4 月 15 日送达公司全体 董事。本次会议由董事长张强先生主持，会议应参加表决董事 9 人，实际参加表 决董事 9 人。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称 "公司法"）等法律法规以及《上海联影医疗科技股份有限公司章程》（以下简称 "公司章程"）的相关规定, 会议决议合法、有效。 （三）审议通过《关于公司 2023 年年度报告及摘要的议案》 公司 2023 年年度报告及摘要的编制和审核符合法律法规及相关规定，报告 内容真实、准确、完整地反映公司 2023 年度的经营情况和财务状况等 ...

2、续聘会计师事务所履行的程序 公司于 2023 年 4 月 26 日、2023 年 6 月 6 日分别召开第一届董事会第十九 次会议和 2022 年年度股东大会审议通过了《关于续聘 2023 年度会计师事务所的 议案》，同意聘任普华永道中天为公司 2023 年度财务审计机构及内部控制审计机 构，公司独立董事对上述议案发表了事前认可意见及同意的独立意见。 一、2023 年年审会计师事务所基本情况 1、会计师事务所的基本情况 普华永道中天前身为 1993 年 3 月 28 日成立的普华大华会计师事务所，经批 准于 2000 年 6 月更名为普华永道中天会计师事务所有限公司；经 2012 年 12 月 24 日财政部财会函[2012]52 号批准，于 2013 年 1 月 18 日转制为普华永道中天 会计师事务所（特殊普通合伙），注册地址为中国（上海）自由贸易试验区陆家 嘴环路 1318 号星展银行大厦 507 单元 01 室。普华永道中天是普华永道国际网络 成员机构，拥有会计师事务所执业证书，具备从事 H 股企业审计业务的资质， 同时也是原经财政部和证监会批准的具有证券期货相关业务资格的会计师事务 所。此外，普 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-016 上海联影医疗科技股份有限公司 关于增加 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易概述 （一）日常关联交易履行的审议程序 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"）于 2024 年 4 月 25 日召开第二届董事会第六次会议审议通过了《关于增加 2024 年度日常 关联交易预计的议案》，表决结果为：赞成 9 票，无反对票，无弃权票。本次日 常关联交易为向关联方深圳市联新移动医疗科技有限公司销售医学影像设备和 配件等，预计增加金额人民币 7,700 万元。据《上海证券交易所科创板股票上市 规则》《上海联影医疗科技股份有限公司章程》等相关规定,本议案无需提交股东 大会审议。 独立董事专门会议审核意见：公司本次增加 2024 年度日常关联交易预计符 合公司经营需要，定价遵循了公平、合理的原则，不存在损害公司及其他股东特 是否需要提交股东大会审议：否 日常关联 ...

上海联影医疗科技股份有限公司 2023 年度独立董事述职报告 报告期内，公司董事会、股东大会的召集、召开均符合法定程序，本人没有 对本年度的董事会议案提出异议的情形，公司董事会审议的所有议案全部表决通 过。本年度出席董事会和股东大会具体情况如下： 本人王少飞，作为上海联影医疗科技股份有限公司（以下简称"公司"或"联 影医疗"）的独立董事，在 2023 年度工作中，严格按照《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等法律法规和《上海联影医疗科技股 份有限公司章程》（以下简称"《公司章程》"）、《上海联影医疗科技股份有限公司 独立董事工作制度》（以下简称"《独立董事工作制度》"）的规定和要求，认真履 行职责，积极出席相关会议，审议董事会各项议案，对相关事项发表独立意见， 发挥了独立董事的作用，维护了公司和股东尤其是中小股东的利益。现将 2023 年度履职情况报告如下： 一、独立董事的基本情况 （一）独立董事个人基本情况 王少飞，男，1 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-012 上海联影医疗科技股份有限公司 2023 年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相 关规定，上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗"） 将公司 2023 年度募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 根据中国证监会核发的《关于同意上海联影医疗科技股份有限公司首次公开 发行股票注册的批复》（证监许可[2022]1327 号），公司获准向社会公开发行人民 币普通股（A 股）10,000 万股，发行价格为 109.88 元/股，募集资金总额 1,098,800 万元。公司募集资金总额扣除所有股票发行费用（包括不含增值税的承销及保荐 费用以及其他发行费用）人民币 264,158,460.63 元后的募集资金净额为人民币 10 ...

证券代码： 688271 证券简称： 联影医疗 公告编号： 2024-010 上海联影医疗科技股份有限公司（以下简称"公司"或"联影医疗））第二 届监事会第三次会议于 2024 年 4 月 25 日在公司会议室召开，会议同时采用了现 场与通讯相结合的表决方式,本次会议通知已于 2024 年 4 月 15 日送达公司全体 监事。本次会议由监事会主席万莉娟女士主持，会议应参加表决监事 3 人, 实际 参加表决监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》等法 律法规以及《上海联影医疗科技股份有限公司章程》（以下简称"公司章程"）的 相关规定, 会议决议合法、有效。 二、监事会会议审议情况 上海联影医疗科技股份有限公司 第二届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 本议案尚需提交公司年度股东大会审议。 （一）审议通过《关于公司 2023 年度监事会工作报告的议案》 根据公司监事会 2023 年度工作情况，公司监事会编制了《2023 年度监事会 工作报告》。 ...